Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Borderline Resectable Pancreatic Cancer × folfirinox × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 8 Rectal Neoplasms 2 Carcinoma, Hepatocellular 2 Urachal cancer 1 Pancreatic Adenocarcinoma 1 Neoplasms 1 Colorectal Neoplasms 1 Borderline Resectable Pancreatic Cancer 1

Interventions

Gemcitabine 2 130-nm albumin-bound paclitaxel 2 irinotecan sucrosofate 1 folfirinox 1 camrelizumab 1 Taxes 1 S 1 (combination) 1 Oxaliplatin 1 Leucovorin 1 Fluorouracil 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02717091 2020-09-10

Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer

Nagoya University

Phase 2 Unknown

Gastrointestinal

Borderline Resectable Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡